vs
BOSTON BEER CO INC（SAM）与Bio-Techne（TECH）财务数据对比。点击上方公司名可切换其他公司
BOSTON BEER CO INC的季度营收约是Bio-Techne的1.5倍（$461.6M vs $311.4M），Bio-Techne同比增速更快（-1.5% vs -4.1%），过去两年Bio-Techne的营收复合增速更高（1.3% vs -10.7%）
波士顿啤酒公司是美国知名酿酒企业，1984年由吉姆·科赫与朗达·卡尔曼联合创立。旗下首款产品以美国开国元勋、独立运动先驱塞缪尔·亚当斯命名，后续陆续推出多个自有品牌，2019年正式完成与角鲨头酿酒厂的合并，是北美精酿啤酒行业的核心参与者之一。
Bio-Techne是美国头部生命科学企业，面向科研、诊断及生物工艺市场需求，研发、生产并销售生命科学试剂、仪器及配套服务，产品及解决方案广泛应用于基础研究、体外诊断、生物医药研发生产等场景，可为相关领域从业者提供可靠的专业工具支持。
SAM vs TECH — 直观对比
营收规模更大
SAM
是对方的1.5倍
$311.4M
营收增速更快
TECH
高出2.6%
-4.1%
两年增速更快
TECH
近两年复合增速
-10.7%
损益表 — Q1 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $461.6M | $311.4M |
| 净利润 | — | $51.0M |
| 毛利率 | 46.4% | 66.9% |
| 营业利润率 | 12.4% | 24.2% |
| 净利率 | — | 16.4% |
| 营收同比 | -4.1% | -1.5% |
| 净利润同比 | — | 126.0% |
| 每股收益（稀释后） | $2.16 | $0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收SAMTECH
| Q1 26 | $461.6M | $311.4M | ||
| Q4 25 | $385.7M | $295.9M | ||
| Q3 25 | $537.5M | — | ||
| Q2 25 | $587.9M | $317.0M | ||
| Q1 25 | $453.9M | $316.2M | ||
| Q4 24 | $402.3M | $297.0M | ||
| Q3 24 | $605.5M | $289.5M | ||
| Q2 24 | $579.1M | $306.1M |
净利润SAMTECH
| Q1 26 | — | $51.0M | ||
| Q4 25 | $-22.5M | $38.0M | ||
| Q3 25 | $46.2M | — | ||
| Q2 25 | $60.4M | $-17.7M | ||
| Q1 25 | $24.4M | $22.6M | ||
| Q4 24 | $-38.8M | $34.9M | ||
| Q3 24 | $33.5M | $33.6M | ||
| Q2 24 | $52.3M | $40.6M |
毛利率SAMTECH
| Q1 26 | 46.4% | 66.9% | ||
| Q4 25 | 43.5% | 64.6% | ||
| Q3 25 | 50.8% | — | ||
| Q2 25 | 49.8% | 62.7% | ||
| Q1 25 | 48.3% | 67.9% | ||
| Q4 24 | 39.9% | 65.3% | ||
| Q3 24 | 46.3% | 63.2% | ||
| Q2 24 | 46.0% | 66.4% |
营业利润率SAMTECH
| Q1 26 | 12.4% | 24.2% | ||
| Q4 25 | -8.6% | 18.4% | ||
| Q3 25 | 11.5% | — | ||
| Q2 25 | 14.0% | -7.5% | ||
| Q1 25 | 7.4% | 12.2% | ||
| Q4 24 | -13.9% | 16.0% | ||
| Q3 24 | 7.6% | 13.8% | ||
| Q2 24 | 12.2% | 15.0% |
净利率SAMTECH
| Q1 26 | — | 16.4% | ||
| Q4 25 | -5.8% | 12.8% | ||
| Q3 25 | 8.6% | — | ||
| Q2 25 | 10.3% | -5.6% | ||
| Q1 25 | 5.4% | 7.1% | ||
| Q4 24 | -9.6% | 11.7% | ||
| Q3 24 | 5.5% | 11.6% | ||
| Q2 24 | 9.0% | 13.3% |
每股收益（稀释后）SAMTECH
| Q1 26 | $2.16 | $0.32 | ||
| Q4 25 | $-1.97 | $0.24 | ||
| Q3 25 | $4.25 | — | ||
| Q2 25 | $5.45 | $-0.11 | ||
| Q1 25 | $2.16 | $0.14 | ||
| Q4 24 | $-3.23 | $0.22 | ||
| Q3 24 | $2.86 | $0.21 | ||
| Q2 24 | $4.39 | $0.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $164.1M | $209.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $682.6M | $2.1B |
| 总资产 | $1.2B | $2.6B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资SAMTECH
| Q1 26 | $164.1M | $209.8M | ||
| Q4 25 | $223.4M | $172.9M | ||
| Q3 25 | $250.5M | — | ||
| Q2 25 | $212.4M | $162.2M | ||
| Q1 25 | $152.5M | $140.7M | ||
| Q4 24 | $211.8M | $177.5M | ||
| Q3 24 | $255.6M | $187.5M | ||
| Q2 24 | $219.3M | $152.9M |
总债务SAMTECH
| Q1 26 | — | — | ||
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M |
股东权益SAMTECH
| Q1 26 | $682.6M | $2.1B | ||
| Q4 25 | $846.3M | $2.0B | ||
| Q3 25 | $911.0M | — | ||
| Q2 25 | $912.3M | $1.9B | ||
| Q1 25 | $897.0M | $2.0B | ||
| Q4 24 | $916.2M | $2.1B | ||
| Q3 24 | $1.0B | $2.1B | ||
| Q2 24 | $1.0B | $2.1B |
总资产SAMTECH
| Q1 26 | $1.2B | $2.6B | ||
| Q4 25 | $1.2B | $2.5B | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.3B | $2.6B | ||
| Q1 25 | $1.2B | $2.6B | ||
| Q4 24 | $1.3B | $2.7B | ||
| Q3 24 | $1.4B | $2.7B | ||
| Q2 24 | $1.4B | $2.7B |
负债/权益比SAMTECH
| Q1 26 | — | — | ||
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
SAM
暂无分部数据
TECH
| Protein Sciences segment revenue | $226.2M | 73% |
| Diagnostics and Spatial Biology segment revenue | $85.6M | 27% |
| Other revenue (1) | $5.4M | 2% |
